In the BioHarmony Drug Report Database
Satralizumab
Enspryng (satralizumab) is an antibody pharmaceutical. Satralizumab was first approved as Enspryng on 2020-08-14. It is used to treat neuromyelitis optica in the USA. It has been approved in Europe to treat neuromyelitis optica.
Trade Name
|
Enspryng |
---|---|
Common Name
|
satralizumab |
ChEMBL ID
|
CHEMBL3833307 |
Indication
|
neuromyelitis optica |
Drug Class
|
Monoclonal antibodies: humanized, immunomodulating |
Image (chem structure or protein)
